David Ziegler
Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (28)
Paediatric central nervous system (CNS) tumours are the leading cause of cancer-related death in children, yet disease monitoring remains challenging. Conventional approaches, including imaging and cytology, lack sensitivity, delaying intervention. Liquid biopsy offers a minimally invasive alternative, but the utility of circulating tumour cells (CTCs) in paediatric CNS tumours as biomarkers is poorly defined. We developed a CTC detection and characterisation workflow from cerebrospinal fluid (CSF) utilising single-cell RNA-sequencing (scRNA-seq) and applied this to ten CNS tumour subtypes in 16 patients. CTCs were identified in all cases, with higher burdens in pineoblastoma, medulloblastoma and atypical teratoid rhabdoid tumours. Longitudinal profiling revealed CTC dynamics correlated with clinical disease course and anticipated relapse. Critically, scRNA-seq uncovered a sub-clonal canonical driver alteration at diagnosis that only became detectable by bulk RNA-seq at progression, underscoring its potential to resolve clonal dynamics. This workflow enables real-time molecular profiling, offering a transformative strategy for disease monitoring and personalised therapy in paediatric brain tumours.
Year:
2025
METRO results from African American (AA), Hispanic/Latino (MX), and European (EA) ancestries at 250kb clumping physical distance thresholds. (contains p-value, heritabilities and Fisher p-value)
Year:
2025
Purpose: High-grade gliomas (HGG) occur in any central nervous system location and at any age. HGGs in teenagers/young adults (TYA) are understudied. This project aimed to characterize these tumors to support accurate stratification of patients. Experimental Design: 207 histone/IDH wild-type tumors from patients aged 13 to 30 years were collected. DNA methylation profiling [Illumina EPIC BeadArrays, brain tumor classifier (MNPv12.8 R package)] classified cases against reference cohorts of HGG. Calibrated scores guided characterization workflows [RNA-based ArcherDx fusion panel ( n = 92), whole-exome sequencing ( n = 107), and histology review). Results: 53.4% ( n = 86) matched as pediatric-type subgroups [pedHGG_RTK1A/B/C (31.7%, n = 51, PDGFRA , CDKN2A/B , SETD2 , and NF1 alterations), pedHGG_ MYCN (8.1%, n = 13, MYCN/ID2 amplifications), and pedHGG_RTK2A/B (7.5%, n = 12, TP53 , BCOR , ATRX , and EGFR alterations)]. Eighteen percent ( n = 29) classified as adult-type subgroups [GBM_MES (15.5%, n = 25, enriched for RB1 , PTEN , and NF1 alterations) and GBM_RTK1/2 (2.5%, n = 4, CDK4 amplifications)]. Twenty-three cases (14.7%) classified as novel, poorly characterized subgroups with distinct methylation profiles and molecular features [pedHGG_A/B ( n = 10 6.2%), HGG_E ( n = 6 3.7%), HGG_B ( n = 2 1.0%), and GBM_CBM ( n = 5 3.1%)] with variable histologic morphology. Eight cases (5.1%) showed hypermutator phenotypes, enriched in HGG_E, one of which was associated with constitutional mismatch repair deficiency, and their sibling, who was diagnosed with the same syndrome, was diagnosed with a tumor that classified as a pedHGG_RTK1B. HGGs that have developed on a background of previous treatment for a childhood cancer are detected in the TYA population, classifying most frequently as pedHGG_RTK1 and contributing to the poor prognosis of this subgroup. Age distribution/molecular profile comparisons using publicly available methylation/sequencing data (and from local diagnostic cohorts) for HGG_B ( n = 19), GBM_CBM ( n = 35), and GBM_MES_ATYP ( n = 102), irrespective of age, show that HGG_B is a TYA-specific subgroup (median age 29 years) and that GBM_CBM and GBM_MES_ATYP show a peak of distribution in the TYA population but also have a wider age distribution (median age 35.7 and 50.5 years, respectively), with the latter showing distinct differences in copy-number profiles compared with older adults in the same subgroup and containing fewer chr7 gains, chr10 losses, more CDKN2A/B deletions and MET amplifications, and a worse survival compared with adult-specific GBM_MES_TYP. Conclusions: TYA HGGs comprise novel methylation subgroups with distinct methylation and molecular profiles. Accurate stratification of these patients will open opportunities to more effective treatments, including immune checkpoint, MAPK pathway, and PDGFRA inhibitors. See related commentary by Ritzmann et al., p. 3110
Year:
2025
METRO-Egger results from African American (AA), Hispanic/Latino (MX), and European (EA) ancestries at 500kb clumping physical distance thresholds. (contains p-value, heritabilities and Fisher p-value)
Year:
2025
METRO results from African American (AA), Hispanic/Latino (MX), and European (EA) ancestries at 500kb clumping physical distance thresholds. (contains p-value, heritabilities and Fisher p-value)
Year:
2025
METRO-Egger results from African American (AA), Hispanic/Latino (MX), and European (EA) ancestries at 250kb clumping physical distance thresholds. (contains p-value, heritabilities and Fisher p-value)
Year:
2025
Background: Hepatoblastoma (HB) is a rare embryonal liver tumor, with an increasing global incidence that underscores the need to understand its genetic etiology. Methods: Utilizing the ancestry-matched expression quantitative loci data, we performed a HB transcriptome-wide association study (TWAS) on 4,539 Europeans, 1,047 Latinos, and 378 African Americans (∼1:10 case–control ratio). We conducted a meta-analysis of multiancestry transcriptome-wide analysis (METRO), followed by METRO-Egger sensitivity analysis and ancestry-specific gene set enrichment analyses. We further explored genes with additional evidence gathered from independent cohorts and databases. Results: Across the three ancestries, the discovered genes shared the same effect direction across ancestries. A meta-analysis of the three ancestries identified 28 genes significantly associated with HB risk, and 15 were nominally significant for at least two ancestries. Our post-TWAS analyses highlighted 8 genes among these 28, including OXER1 (meta-analysis P value = 7.34 × 10 −6 ), FADS1 ( P value = 4.01 × 10 −6 ), and UGDH ( P value = 5.29 × 10 −8 ), which were expressed in fetal liver hepatoblast cells and were differentially expressed in tumor and normal tissues in an independent Japanese HB study (P values = 2.61 × 10 −13 , 3.62 × 10 −3 , and 1.95 × 10 −9 , respectively). Conclusions: We pinpointed eight potential genes associated with HB using data from an ongoing multiancestry genome-wide association study. Impact: We conducted the largest HB TWAS to date, prompting further exploration of genes.
Year:
2025
Supplementary figure 1 A, Bar plot showing the frequency of age distribution across the TYA cohort, and the gender proportions. Blue representing male, pink representing female. B, Pie chart representing the original diagnoses of the TYA cohort, coloured according to the labels provided.
Year:
2025
Purpose: Tropomyosin receptor kinase (TRK) fusions are detected in less than 2% of central nervous system tumors. There are limited data on the clinical course of affected patients. Experimental Design: We conducted an international retrospective cohort study of patients with TRK fusion–driven central nervous system tumors. Results: A total of 119 patients were identified. The median age at the time of diagnosis was 4.5 years. The majority were reported to have a histology consistent with a diagnosis of high-grade glioma (HGG; 57.1%) followed by low-grade glioma (LGG; 27.7%). Pediatric patients had a better prognosis, with a median overall survival of 185.5 months compared with 24.8 months in adults ( P P = 0.0012). The objective response was 68.8% with larotrectinib compared with 38.1% for nontargeted treatment. Conclusions: Children with LGG had a favorable outcome compared with adult glioma and HGG. TRK inhibitors seem to improve tumor control.
Year:
2025
Supplementary Data S1. Definition of response, Description of response criteria used by sites to evaluate tumor response, Definition of extend of resection, Definition of extend of resection used by sites.
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (84)
Daniel A. Morgenstern
Royal Marsden NHS Foundation Trust
Marcel Dinger
Dean
University of Sydney
CAROLINA ARMENGOL
Principal Investigator- Childhood Liver Oncology group
-
Fatima Valdes-Mora
Team Leader
Children's Cancer Institute Australia
Jenny Poynter
Professor
University of Minnesota
Roland Kappler
LMU University Hospital
Adam Resnick
Director
University of Pennsylvania
Ryuma Tanaka
Assistant Professor
Nationwide Children's Hospital
Mariella Spalato Ceruso
Institut Bergonié
David Malkin
University of Toronto
Jordan R Hansford
Oncologist
University of Melbourne
Tianzhong Yang
University of Minnesota
Derek S. Tsang
Staff Radiation Oncologist
-
Uri Tabori
Section Head of Neuro-Oncology
Hospital for Sick Children
Frank Lin
Baylor College of Medicine Department of Pediatrics
Holly Lindsay
Associate Professor
University of Colorado Health
Ingrid Øra
MD, PhD, Assoc Prof
Lund University
Birgit Geoerger
Université Paris-Saclay
Benjamin Rayner
Senior Scientist
Children's Cancer Institute Australia
David Lewis Lawrence
Conjoint Lecturer
UNSW Sydney
Maria Vinci
Principal Investigator
Ospedale Pediatrico Bambino Gesù
Eugene Hwang
Chief
Children's National Medical Center
Alexander Drilon
Thomas Jefferson University Hospital
Chantel Cacciotti
Western University
Chris Jones
Professor of Childhood Brain Tumour Biology
Institute of Cancer Research
Maura Massimino
Direttore S.C
Fondazione IRCCS Istituto Nazionale dei Tumori
Kathryn McFadden
Associate Clinical Professor
Izaak Walton Killam Health Centre
elisabetta schiavello
Fondazione IRCCS Istituto Nazionale dei Tumori
Adam Shlien
Wellcome Sanger Institute
Daniel Orbach
-
Paul Ekert
Group Leader, Translational Tumour Biology
Children's Cancer Institute Australia
Sabine Mueller
Adjunt Associate Professor
University of California
Anita Villani
Hospital for Sick Children
Christopher L Moertel
University of Minnesota
Nathan Robison
Assistant Professor of Clinical Pediatrics
University of Southern California Keck School of Medicine
Maria Tsoli
Senior Scientist
Children's Cancer Institute Australia
Sebastian Brandner
University College London
Timothy N. Phoenix
Assistant Professor
University of Cincinnati
Ute Bartels
University of Toronto
Eiso Hiyama
Professor
Hiroshima University
Kim Erika Nichols
Full Member
St. Jude Children's Research Hospital
Nicholas Gottardo
University of Western Australia
Rawan Hammad
Assistant professor
king abdulaziz university
Gail Tomlinson
Professor
The University of Texas Health Science Center at Houston
Nada Jabado
Professor
McGill University
Evelina Miele
Associate Medical Director
Ospedale Pediatrico Bambino Gesù
Carl Koschmann
University of Michigan Medical School
Mark Cowley
Conjoint Professor
University of New South Wales
Kathreena M Kurian
University of Bristol
Delphine Boche
Professor of Neuroimmunopathology
University of Southampton
Andrea T. Franson
-
Saonli Basu
Professor
University of Minnesota
Lenka Krsková
First Faculty of Medicine Charles University and University Hospital Motol
Theodore Laetsch
Associate Professor
Children's Hospital of Philadelphia
Michal Zapotocky
University Hospital in Motol
Gad Getz
Broad Institute
Federico Roncaroli
The University of Manchester
Vanessa Tyrrell
Co-Head of Division - Peronalised Medicine
Children's Cancer Institute Australia
Andrew Moore
Associate Professor
University of Queensland
Erin L Marcotte
Faculty, Associate Professor
University of Minnesota
Michael Scheurer
Professor
Baylor College of Medicine
Audrey-Anne Lamoureux
Université de Montréal
Eric Bouffet
Neuro-Oncologist
Hospital for Sick Children
Donald Parsons
Professor
Baylor College of Medicine
Birgit Ertl-Wagner
Radiologist-in-Chief
Hospital for Sick Children
Eve Roman
University of York
Alexander G. Weil
-
Holly Holliday
Children's Cancer Institute Australia
Wayne Nicholls
Clinical Director and Associate Professor
University of Queensland
Peter Downie
Head of Unit
Monash Health
Robert Weatheritt
Associate Professor
UNSW Sydney
Chelsea Mayoh
Children's Cancer Institute Australia
Vijay Ramaswamy
Associate Professor
University of Toronto
Trevor J. Pugh
Professor
University Health Network
CHI KIN IP
Children's Cancer Institute Australia
Anirban Das
Hospital for Sick Children
Logan Spector
Faculty, Professor
University of Minnesota
Marion Mateos
University of New South Wales
Peter B. Dirks
-
Darren Hargrave
University College London
Angela Mastronuzzi
Associate Professor
Università Cattolica del Sacro Cuore
Yosef Maruvka
Assistant professor
Technion - Israel Institute of Technology
R. Stephanie Huang
Faculty, Professor
University of Minnesota
Nicolas U. Gerber
University Children's Hospital Zurich
Make your next move.
Prepare your application
Review drafts before you send them.